[HTML][HTML] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas, MK Siddiqui, P Gupta… - Lung cancer, 2017 - Elsevier
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
[引用][C] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas, MK Siddiqui, P Gupta… - Lung Cancer, 2017 - cir.nii.ac.jp
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection
from a systematic literature review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
from a systematic literature review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas… - Lung cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
[PDF][PDF] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas, MK Siddiqui, P Gupta… - Lung …, 2017 - researchgate.net
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
[HTML][HTML] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
R Brody, Y Zhang, M Ballas, MK Siddiqui… - Lung …, 2017 - lungcancerjournal.info
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
R Brody, Y Zhang, M Ballas, MK Siddiqui… - Lung Cancer …, 2017 - europepmc.org
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …